

HETEROCYCLES, Vol. 73, 2007, pp. 241 - 247. © The Japan Institute of Heterocyclic Chemistry  
Received, 3rd July, 2007, Accepted, 1st October, 2007, Published online, 2nd October, 2007. COM-07-S(U)49

## NUCLEOPHILIC ASYMMETRIC EPOXIDATION CATALYZED BY CYCLIC GUANIDINES<sup>†</sup>

Tetsuya Kita,<sup>2</sup> Bongki Shin,<sup>1</sup> Yuichi Hashimoto,<sup>2</sup> and Kazuo Nagasawa<sup>1\*</sup>

<sup>1</sup>Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Koganei, Tokyo 184-8588, Japan. knaga@cc.tuat.ac.jp

<sup>2</sup>Institute of Molecular and Cellular Biosciences, University of Tokyo, Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.

**Abstract** – Asymmetric nucleophilic epoxidation of chalcone and its derivatives was studied using chiral cyclic guanidine compounds. Pentacyclic guanidine **1a**, which has a characteristic closed-type cavity, catalyzed the reaction to give epoxides with 39-60% *ee*. The newly developed tricyclic guanidine **4** drastically accelerated the reaction, and induced the asymmetric induction of chalcones with almost the same level of **1a**.

Development of novel efficient catalysts for asymmetric reactions is one of the important and challenging topics in synthetic organic chemistry. Phase-transfer catalysts (PTCs) are particularly attractive since they have some advantages over homogeneous catalysts, and many efficient asymmetric PTCs have been explored.<sup>1</sup> In the course of our studies aimed at the development of PTCs, we have reported the pentacyclic guanidine catalyst **1** (Figure 1).<sup>2</sup> The structures of **1** were rationally designed to have a C<sub>2</sub>-symmetrical chiral reaction cavity around the guanidine group; i.e., a substrate recognition/activation site. One of these catalysts, **1a**, which has a closed-type cavity and methyl substituents on its ether rings, was found to induce the high enantioselectivity in the alkylation reaction of the Schiff base imine.<sup>2b</sup> In this communication, we describe the asymmetric nucleophilic epoxidation to  $\alpha,\beta$ -unsaturated ketones catalyzed by **1** and newly synthesized tricyclic guanidine **4**.

Among asymmetric epoxidation, catalytic asymmetric epoxidation of electron-deficient olefins is one of

the most important classes of reactions.<sup>3,4</sup> Recently, asymmetric nucleophilic epoxidation reaction in the presence of chiral guanidine catalysts has been reported by Taylor et al.,<sup>5</sup> Murphy et al.,<sup>6</sup> and Ishikawa et al.<sup>7</sup> We first examined our pentacyclic guanidine compounds **1a** and **1b** as catalyst for the epoxidation reaction to the electron deficient alkenes.





Figure 1. Structures of chiral pentacyclic guanidine **1a** and **1b**, and their X-ray.

Nucleophilic epoxidation reaction of *trans*-chalcone (**2a**) using *tert*-butyl hydroperoxide (TBHP) (5 equivalents) in the presence of **1a** and/or **1b** (10 mol%) was examined in an aqueous 1M KOH/dichloromethane biphasic solution conditions (Table 1). In the case of the reaction with **1a** at room temperature, **3a** was obtained in 76% yield and 22% *ee* (entry 2). Lowering the temperature at 0 °C improved the enantioselectivity up to 39% *ee* (entry 3). When toluene was used instead of dichloromethane, no enantioselectivity was observed (entry 4). In the case of the catalysts **1b**, which has an open-type cavity, **3a** was obtained in 95%, although enantiomeric excess was only 10% (entry 5).



entry	<b>1</b>	temp (°C)	time (h)	yield (%)	ee% <sup>a</sup>
1	---	rt	26	10	---
2	<b>1a</b>	rt	26	76	22
3	<b>1a</b>	0	110	35	39
4	<b>1a</b>	0	40	55	4 <sup>b</sup>
5	<b>1b</b>	0	130	95	10

<sup>a</sup>Enantiomeric excess of **3a** was determined by HPLC analysis (DAICEL Chiralcel OD-H). Absolute configuration was determined by comparison of the HPLC retention time and  $[\alpha]_D$  value with reported authentic sample data.<sup>ref 8</sup> <sup>b</sup>Toluene was used instead of dichloromethane.

Table 1. Nucleophilic epoxidation of **2a** in the presence of chiral pentacyclic guanidine **1**.

These results are interpreted as follows based upon the alkylation reaction of Schiff base imine in the presence of **1** (Figure 2).<sup>2b</sup> Carbonyl group in chalcone (**2a**) coordinates with guanidine in **1** through hydrogen bonding, and a nucleophilic attack of the oxidant (TBHP) takes place from the less hindered side to give (2*S*,3*R*)-**3a** as the major product. The structure of **1a**, which has a closed-type cavity and methyl substituents on the ether rings, effectively controlled the nucleophile approach. On the other hand, control of the nucleophile approach was not sufficient by the structure of **1b**, which has open-type cavity, although it was effective for the acceleration of the reaction.





Figure 2. Epoxidation mechanism of **2a** in the presence of pentacyclic guanidine catalysts **1a**.

Epoxidation reaction of the chalcone derivatives **2b-f** was examined in the presence of catalyst **1a** (Table 2). The 2-naphthyl and 1-naphthyl substituted derivatives **2b** and **2c** gave **3b** and **3c** in 50% and 60% *ee*, respectively (entries 1 and 2).<sup>8,9</sup> On the other hand, the enantiomeric excess was 35% in case of anthracenyl derivative **2d** (entry 3).<sup>10</sup>



entry	<b>2</b>	R	product	time (h)	yield (%)	ee% <sup>a</sup>
1	<b>2b</b>	2-naphthyl	<b>3b</b>	140	51	50
2	<b>2c</b>	1-naphthyl	<b>3c</b>	140	77	60
3	<b>2d</b>	9-anthracenyl	<b>3d</b>	140	>99	35
4	<b>2e</b>	4-nitrophenyl	<b>3e</b>	130	82	38
5	<b>2f</b>	4-methoxyphenyl	<b>3f</b>	160	22	36

<sup>a</sup>Enantiomeric excess of **3** was determined by HPLC analysis.

Table 2. Nucleophilic epoxidation of **2** in the presence of chiral pentacyclic guanidine **1a**.

Reaction with **2e** and **2f**, which have similar molecular sizes as **2a**, gave similar levels of asymmetric induction as **2a**.<sup>9</sup>

In all cases, the enantiomeric excesses of **3** were moderate, however, reaction times were long (130-160 h). To improve the catalytic activity of **1a**, we designed the novel tricyclic guanidine **4** (Figure 3). The tricyclic guanidine **4** has an open-type cavity similar to **1b**, and two benzyl groups overhang to the up and/or down direction with respect to the tricyclic guanidine plane. The open-type cavity in **4** was expected to improve the reactivity, and the two benzyl groups were anticipated to control the nucleophile approach. The  $\pi$ - $\pi$  interaction of phenyl groups between **4** and **2** was also expected to fix the reactive complex conformation of **4** and **2**.





Figure 3. Design of novel tricyclic guanidine **4** and its prospective mechanism for epoxidation.


The chiral tricyclic guanidine **4** was synthesized based upon the 1,3-dipolar cycloaddition reaction protocol (Scheme 1).<sup>11</sup> Reaction of the optically active nitrone **5**<sup>12</sup> with allylbenzene gave the isoxazolidine **6** in 79% yield. The oxidation of the isoxazolidine **6** with *m*-CPBA effected regioselective ring cleavage to give the nitrone **7**. A second 1,3-dipolar cycloaddition reaction of **7** with allylbenzene was conducted, and subsequent reduction of the N-O bond with NaBH<sub>4</sub> in the presence of Mo(O)<sub>6</sub> gave the 2,5-disubstituted pyrrolidine **9** in 38% yield (3 steps). After guanylation of **9** with bis-Cbz-2-methyl-2-pseudourea in the presence of HgCl<sub>2</sub>, tricyclic guanidine was constructed under the Mitsunobu conditions followed by mesylation. Finally, Cbz group was deprotected with hydrogen over 10% Pd/C to give **4** in 30% yield (4 steps).

The epoxidation reaction of **2a-d** was then examined in the presence of **4** (Table 3).<sup>13</sup> In all cases, the reaction was drastically accelerated to give **3a-d** in quantitative yield, and the enantiomeric excesses were

found to be 52, 52, 41 and 30% *ee*, respectively. Thus, the catalytic activity of **1a** was improved by the tricyclic guanidine **4** without losing the moderate enantioselection of **1a**.



Scheme 1. Synthesis of novel tricyclic guanidine **4**. (a) Allylbenzene, toluene, 90°C, 79%; (b) *m*-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, 0°C; (c) Allylbenzene, toluene, 90°C, 60% (2 steps); (d) NaBH<sub>4</sub>, Mo(CO)<sub>6</sub>, CH<sub>3</sub>CN:H<sub>2</sub>O = 7:1, 64%; (e) bis-Cbz-2-methyl-2-pseudourea, HgCl<sub>2</sub>, NEt<sub>3</sub>, DMF, 69%; (f) DEAD, PPh<sub>3</sub>, toluene; (g) NaH, MeOH, THF; (h) MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (i) Pd/C, H<sub>2</sub>, MeOH, 30% (4 steps).



entry	<b>2</b>	R	product	time (h)	yield (%)	ee% <sup>a</sup>
1	<b>2a</b>	phenyl	<b>3a</b>	26	>99	52
2	<b>2b</b>	2-naphtyl	<b>3b</b>	20	>99	52
3	<b>2c</b>	1-naphtyl	<b>3c</b>	20	>99	41
4	<b>2d</b>	anthracenyl	<b>3d</b>	24	>99	30

<sup>a</sup>Enantiomeric excess of **3a** was determined by HPLC analysis.

Table 3. Nucleophilic epoxidation of **2** in the presence of chiral tricyclic guanidine **4**.

In summary, nucleophilic epoxidation reaction of chalcone and its derivatives was examined in the presence of chiral cyclic guanidine catalysts **1** and **4**. In case of the pentacyclic guanidine **1**, closed-type **1a** was effective for the asymmetric induction, and moderate enantiomeric excess of **3** was obtained. The newly developed tricyclic guanidine **4** drastically accelerated the reaction, and induced the chirality of epoxide **3** with almost the same level of **1a**. Further improvements of the catalyst based upon the structure of **4** are in progress.

## ACKNOWLEDGEMENTS

This research was supported in part by grants from Mitsubishi Chemical Corporation, the Uehara Memorial Foundation, and the Nagase Science and Technology Foundation.

## REFERENCES AND NOTES

†We would like to dedicate this communication to Professor Ivar Ugi.

1. a) E. V. Dehmlow and S. S. Dehmlow, *Phase Transfer Catalysis*, 3rd ed.; VCH:Weinheim, 1993. b) C. M. Starks, C. L. Liotta, and M. Halpern, *Phase-Transfer Catalysis*; Chapman and Hall: New York, NY, 1994. c) *Handbook of Phase-Transfer Catalysis*; ed. by Y. Sasson and R. Neumann; Blackie Academic and Professional: London, 1997. d) *Phase-Transfer Catalysis*; ed. by M. E. Halpern; ACS Symposium Series 659; American Chemical Society: Washington, DC, 1997. Recent reviews on asymmetric phase-transfer catalysis, see: e) T. Shioiri, *Handbook of Phase-Transfer Catalysis*; ed. by Y. Sasson and R. Neumann; Blackie Academic and Professional: London, 1997, Chapter 14. f) M. J. O'Donnell, *Catalytic Asymmetric Syntheses*, 2nd ed.; ed. by I. Ojima; Wiley-VCH: New York, NY, 2000; Chapter 10. g) T. Shioiri and S. Arai, *Stimulating Concepts in Chemistry*; ed. by F. Vogtle, J. F. Stoddart, and M. Shibasaki; Wiley-VCH: Weinheim, 2000; p. 123. h) M. J. O'Donnell, *Aldrichimica Acta*, 2001, **34**, 3. i) K. Maruoka and T. Ooi, *Chem. Rev.*, 2003, **103**, 3013. j) M. J. O'Donnell, *Acc. Chem. Res.*, 2004, **37**, 506. k) B. Lygo and B. I. Andrews, *Acc. Chem. Res.*, 2004, **37**, 518.
2. a) K. Nagasawa, A. Georgieva, and T. Nakata, *Tetrahedron*, 2001, **57**, 8959. b) T. Kita, A. Georgieva, Y. Hashimoto, T. Nakata, and K. Nagasawa, *Angew. Chem. Int. Ed.*, 2002, **41**, 2832.
3. For recent reviews on asymmetric epoxidation of electrone deficient olefins, see: a) M. J. Porter and J. Skidmore, *Chem. Commun.*, 2000, 1215. b) T. Nemoto, T. Ohshima, and M. Shibasaki, *J. Synth. Org. Chem. Jpn.*, 2002, **60**, 94. c) Y. Shi, *Acc. Chem. Res.*, 2004, **37**, 488.
4. a) M. Bougauchi, S. Watanabe, T. Arai, H. Sasai, and M. Shibasaki, *J. Am. Chem. Soc.*, 1997, **119**, 2329. b) T. Nemoto, T. Ohshima, K. Yamaguchi, and M. Shibasaki, *J. Am. Chem. Soc.*, 2001, **123**, 2725.
5. a) J. C. McManus, J. S. Carey, and R. J. K. Taylor, *Synlett*, 2003, **3**, 365. b) J. C. McManus, T. Genski, J. S. Carey, and R. J. K. Taylor, *Synlett*, 2003, **3**, 369.
6. M. T. Allingham, A. H.-Jones, P. J. Murphy, D. A. Thomas, and P. W. R. Caulkett, *Tetrahedron Lett.*, 2003, **44**, 8677.
7. T. Kumamoto, K. Ebine, M. Endo, Y. Araki, Y. Fushimi, I. Miyamoto, T. Ishikawa, T. Isobe, and K. Fukuda, *Heterocycles*, 2005, **66**, 347.
8. a) B. Lygo and P. G. Wainwright, *Tetrahedron Lett.*, 1998, **39**, 1599. b) B. Lygo and P. G.

- Wainwright, *Tetrahedron*, 1999, **55**, 6289. c) B. Lygo and D. C. M. To, *Tetrahedron Lett.*, 2001, **42**, 1343.
9. a) E. J. Corey and F. Y. Zhang, *Org. Lett.*, 1999, **1**, 1287. b) T. Ooi, D. Ohara, M. Tamura, and K. Maruoka, *J. Am. Chem. Soc.*, 2004, **126**, 6844.
10. Absolute configuration of **3d** was not determined. Spectral Data for **3d**:  $[\alpha]_D^{23} = -26.3$  (*c* 0.9, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 Mhz, CDCl<sub>3</sub>)  $\delta$  8.50-8.45 (m, 3H), 8.25 (m, 2H), 8.05-8.03 (m, 2H), 7.71 (m, 1H), 7.60-7.49 (m, 6H), 5.01 (d, *J* = 2.1 Hz, 1H), 4.49 (d, *J* = 2.1 Hz, 1H). HPLC (DAICEL Chiral OD-H): 7% dioxane-hexane, 0.5 mL/min, 46.5 min (minor), 69.2 min (major).
11. a) K. Nagasawa, T. Ishiwata, Y. Hashimoto, and T. Nakata, *Tetrahedron Lett.*, 2002, **43**, 6383. b) T. Ishiwata, T. Hino, H. Koshino, Y. Hashimoto, T. Nakata, and K. Nagasawa, *Org. Lett.*, 2002, **4**, 2921. c) J. Shimokawa, K. Shirai, A. Tanatani, Y. Hashimoto, and K. Nagasawa, *Angew. Chem. Int. Ed.*, 2004, **43**, 1559. d) J. Shimokawa, T. Ishiwata, K. Shirai, H. Koshino, A. Tanatani, T. Nakata, Y. Hashimoto, and K. Nagasawa, *Chem. Eur. J.*, 2005, **11**, 6878.
12. A. Goti, M. Cacciarini, F. Cardona, and A. Brandi, *Tetrahedron Lett.*, 1999, **40**, 2853.
13. Typical procedure for epoxidation of **2a** in the presence of **4**. A mixture of **2a** (10 mg, 0.05 mmol) and **4** (3 mg, 0.005 mmol) in dichloromethane (0.2 mL) and 1M KOH solution (0.25 mL) was cooled at 0 °C. To the mixture was added TBHP (5M in decane, 0.05 mL, 0.25 mmol), and the resulting mixture was stirred at 0 °C for 26 h. The reaction mixture was added H<sub>2</sub>O, and extracted with dichloromethane. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel to give **3a** (11 mg, 99%, 52% *ee*).